Abstract Number: 1506 • ACR Convergence 2023
Prescribing Patterns in Lupus Nephritis: Analyzing Time from Proteinuria to Prescription of ACE/ARB
Background/Purpose: Black patients with lupus nephritis have worse renal outcomes compared with their White counterparts. Currently, there is a paucity of data evaluating the use…Abstract Number: 2274 • ACR Convergence 2023
Lupus Low Disease Activity State as an Attainable Target in Lupus Nephritis Associated with Reduced Risk of Relapse
Background/Purpose: Lupus nephritis (LN) is a significant comorbidity affecting approximately up to 50-60% of patients with systemic lupus erythematosus (SLE). Complete renal response (CRR) and…Abstract Number: 2535 • ACR Convergence 2023
Strategies to Embrace Living with Lupus Fearlessly (SELF): A Promising Digital Intervention for Lupus Self-Management
Background/Purpose: The Lupus Foundation of America (LFA) has engaged in a 5-year cooperative agreement with the Centers for Disease Control and Prevention to implement a…Abstract Number: 0556 • ACR Convergence 2023
Classical Complement Activation in Lupus Nephritis Correlates with Disease Biomarkers: Results from Two Observational Studies
Background/Purpose: Lupus nephritis (LN) is an autoantibody-mediated disease that can activate C1q and the classical complement pathway. Pathogenic anti-C1q antibodies (PACAs) are often present, amplifying…Abstract Number: 0888 • ACR Convergence 2023
Functionally Selective Immunomodulator Shows Robust Efficacy in Spontaneous Lupus Mouse Model
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous autoimmune disease. There is still a high unmet need to improve current treatment options. Type 1…Abstract Number: 1447 • ACR Convergence 2023
Increased Left Ventricular Mass Index in Systemic Lupus Erythematosus Patients with Lupus Nephritis Compared to Those Without Nephritis
Background/Purpose: Patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) are at increased risk of cardiovascular (CV) morbidity and mortality, compared to those without…Abstract Number: 1509 • ACR Convergence 2023
Calcineurin Inhibitors for Treatment of Lupus Nephritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background/Purpose: The current recommendations for the treatment of LN consider as the standard of care (SoC) the use of MMF or CYC. Considering the expanding…Abstract Number: 2275 • ACR Convergence 2023
Lupus Low Disease Activity State Ameliorates the Poor Prognosis in Lupus Nephritis Patients with anti-Sm Autoantibody
Background/Purpose: Anti-Sm autoantibody has been a known specific biomarker of systemic lupus erythematosus (SLE). There have been reports about its correlation with higher disease activity,…Abstract Number: 2552 • ACR Convergence 2023
Inflammatory Fibrosis Precedes Loss of Kidney Function in Lupus Nephritis
Background/Purpose: Interstitial fibrosis in lupus nephritis (LN) is often infiltrated by immune cells. However, this is typically regarded as nonspecific "scar reaction" rather than active…Abstract Number: 0560 • ACR Convergence 2023
Genetic Determinants of Lupus Nephritis and Kidney Function in Systemic Lupus Erythematosus
Background/Purpose: Lupus nephritis (LN) is one of the most common and severe manifestation of SLE. Risk factors for lupus nephritis and renal function decline are…Abstract Number: 0893 • ACR Convergence 2023
Involvement of Type I Interferon-responsive Myeloid Cells in Renal Inflammation in a Lupus Mouse Model
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease that can cause damage to multiple organs, including the kidneys in Lupus Nephritis (LN). Current treatments…Abstract Number: 1457 • ACR Convergence 2023
Obesity Is an Independent Poor Prognostic Factor in Lupus Nephritis
Background/Purpose: Up to 50% of patients suffering from systemic lupus erythematosus (SLE) develop lupus nephritis (LN) within the first 10 years of diagnosis and 5…Abstract Number: 1511 • ACR Convergence 2023
B-Cell Recovery in a Randomized Controlled Trial of B-Cell Depletion with Obinutuzumab for the Treatment of Proliferative Lupus Nephritis
Background/Purpose: Patients with LN who received obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, with standard-of-care (MMF) immunosuppression (Phase II NOBILITY; NCT02550652; PMID 34615636) showed…Abstract Number: 2289 • ACR Convergence 2023
Short and Long Term Outcomes of Patients with Pure Membranous Lupus Nephritis Compared to Patients with Proliferative Disease
b>Background/Purpose: Patients with pure membranous lupus nephritis (LN) are known to have a different disease course than those with proliferative disease. The aim of this…Abstract Number: 2589 • ACR Convergence 2023
Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Systemic Lupus Erythematosus
Background/Purpose: Chronic glucocorticoid (GC) morbidity is rarely captured as a standardized clinical outcome in pediatric rheumatic conditions. The pediatric glucocorticoid toxicity index (pGTI) (Brogan et…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 31
- Next Page »